Related references
Note: Only part of the references are listed.A global perspective on the issue of access to insulin
David Beran et al.
DIABETOLOGIA (2021)
Addressing Insulin Access and Affordability: An Endocrine Society Position Statement
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study
Thomas C. Blevins et al.
DIABETES OBESITY & METABOLISM (2020)
Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
Antonio Nicolucci et al.
DIABETES THERAPY (2020)
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
Justin M. Gregory et al.
DIABETES (2019)
Evolution of the EU Biosimilar Framework: Past and Future
Elena Wolff-Holz et al.
BIODRUGS (2019)
Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
Karla F. S. Melo et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Cost-Related Insulin Underuse Among Patients With Diabetes
Darby Herkert et al.
JAMA INTERNAL MEDICINE (2019)
Relationship between health care insurance status, social determinants and prevalence of diabetes-related microvascular complications in patients with type 1 diabetes: a nationwide survey in Brazil
Marilia Brito Gomes et al.
ACTA DIABETOLOGICA (2019)
Insulin prices, availability and affordability in 13 low-income and middle-income countries
Margaret Ewen et al.
BMJ GLOBAL HEALTH (2019)
Insulin Access and Affordability Working Group: Conclusions and Recommendations
William T. Cefalu et al.
DIABETES CARE (2018)
Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients
Zahra Razavi et al.
ENDOCRINE (2018)
Introduction of biosimilar insulins in Europe
M. Davies et al.
DIABETIC MEDICINE (2017)
Financial costs for families of children with Type 1 diabetes in lower-income countries
G. D. Ogle et al.
DIABETIC MEDICINE (2016)
Euglycaemic glucose clamp: what it can and cannot do, and how to do it
Tim Heise et al.
DIABETES OBESITY & METABOLISM (2016)
Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil
M. B. Gomes et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Constraints and challenges in access to insulin: a global perspective
David Beran et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection
Paola Lucidi et al.
DIABETES CARE (2015)
Insulin Analogs-Is There a Compelling Case to Use Them? No!
Mayer B. Davidson
DIABETES CARE (2014)
Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
Linda Morrow et al.
DIABETES CARE (2013)
THE IMPACT OF THE POLISH HUMAN INSULIN (GENSULIN) ON PUBLIC PAYER'S EXPENDITURE IN 2001-2013
J. Orlewski et al.
VALUE IN HEALTH (2013)
Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: A nationwide multicenter study in Brazil
Marilia B. Gomes et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
The insulin dilemma in resource-limited countries. A way forward?
G. V. Gill et al.
DIABETOLOGIA (2011)
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Sumeet R. Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus
J Plank et al.
ARCHIVES OF INTERNAL MEDICINE (2005)